ROCKET PHARMACEUTICALS INC's ticker is RCKT and the CUSIP is 77313F106. A total of 147 filers reported holding ROCKET PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $345,174 | +17.1% | 16,846 | +13.6% | 0.00% | – |
| Q2 2023 | $294,712 | +19.9% | 14,832 | +3.3% | 0.00% | – |
| Q1 2023 | $245,850 | -11.9% | 14,352 | +0.6% | 0.00% | – |
| Q4 2022 | $279,126 | +42.4% | 14,263 | +15.9% | 0.00% | – |
| Q3 2022 | $196,000 | +21.7% | 12,308 | +5.6% | 0.00% | – |
| Q2 2022 | $161,000 | +22.9% | 11,651 | +41.0% | 0.00% | – |
| Q1 2022 | $131,000 | -28.0% | 8,261 | -0.3% | 0.00% | – |
| Q4 2021 | $182,000 | -29.7% | 8,290 | -4.0% | 0.00% | – |
| Q3 2021 | $259,000 | -29.6% | 8,637 | +4.1% | 0.00% | – |
| Q2 2021 | $368,000 | +8.9% | 8,297 | +8.5% | 0.00% | – |
| Q1 2021 | $338,000 | -27.8% | 7,646 | -10.6% | 0.00% | – |
| Q4 2020 | $468,000 | +127.2% | 8,551 | -4.8% | 0.00% | – |
| Q3 2020 | $206,000 | +9.6% | 8,980 | 0.0% | 0.00% | – |
| Q2 2020 | $188,000 | +40.3% | 8,980 | -6.5% | 0.00% | – |
| Q1 2020 | $134,000 | – | 9,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| M28 Capital Management LP | 715,880 | $11,354,000 | 10.44% |
| RTW INVESTMENTS, LP | 15,802,802 | $250,632,000 | 5.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 63,000 | $17,884,000 | 4.03% |
| TANG CAPITAL MANAGEMENT LLC | 1,265,900 | $20,077,000 | 4.02% |
| Prosight Management, LP | 203,268 | $3,224,000 | 2.08% |
| COWEN AND COMPANY, LLC | 1,000,000 | $15,860,000 | 1.53% |
| Boxer Capital, LLC | 1,466,051 | $23,252,000 | 1.20% |
| Cormorant Asset Management, LP | 868,550 | $13,775,000 | 1.06% |
| Amitell Capital Pte Ltd | 97,331 | $1,544,000 | 0.90% |
| SECTORAL ASSET MANAGEMENT INC | 303,975 | $4,821,000 | 0.86% |